Female Reproductive & Breast

Endometriosis: diagnosis and management

Clinical Overview and When to Suspect Endometriosis

— Affects ~6–10% of reproductive-age women; up to 30–50% of women with infertility and 70–90% of those with chronic pelvic pain.

— Peak diagnosis age 25–35; average diagnostic delay 7–10 years from symptom onset.

— Cyclic dysmenorrhea that progressively worsens, starts before menses, and is refractory to NSAIDs/OCPs.

— Deep dyspareunia, dyschezia, dysuria timed to menses.

— Infertility with otherwise normal initial workup.

— Chronic pelvic pain >6 months in reproductive-age woman.

— Cyclic hematuria, hematochezia, or shoulder-tip pain (rare extra-pelvic disease).

— Early menarche (<11), short cycles (<27 days), heavy/prolonged menses, nulliparity.

— Low BMI, müllerian anomalies with outflow obstruction, first-degree relative with endometriosis (7–10× risk).

— Protective: multiparity, prolonged lactation, late menarche.

— Estrogen drives lesion growth via local aromatase activity; progesterone resistance perpetuates inflammation.

— Prostaglandin and cytokine release (IL-6, TNF-α) cause pain and adhesions.

Board pearl: Any reproductive-age woman with cyclic pelvic pain + infertility + normal pelvic ultrasound still warrants strong suspicion for endometriosis — imaging is insensitive for superficial peritoneal disease, and empirical treatment is acceptable before laparoscopy per ACOG.

Definition: Endometriosis is the presence of endometrial-like glands and stroma outside the uterine cavity, most commonly on the pelvic peritoneum, ovaries (endometriomas), uterosacral ligaments, and rectovaginal septum. It is a chronic, estrogen-dependent, inflammatory disease driven by retrograde menstruation, coelomic metaplasia, and altered immune surveillance.

Epidemiology:

When to suspect (Step 3 outpatient framing):

Risk factors:

Pathophysiology high-yield points:

Presentation Patterns and Key History

— Begins 1–2 days before menses, peaks with flow, often radiates to back/thighs.

— Initially cyclic, becomes chronic and non-cyclic over time as central sensitization develops.

— Poor correlation between disease stage and pain severity — Stage I disease can be exquisitely painful; Stage IV may be silent (often the infertility presentation).

— Uterosacral/rectovaginal nodules: deep dyspareunia, dyschezia, tenesmus.

— Bladder implants: dysuria, urinary frequency, cyclic hematuria.

— Bowel implants: cyclic hematochezia, constipation, bloating ("endo belly").

— Diaphragmatic/thoracic: catamenial pneumothorax, hemoptysis, shoulder pain — rare but classic.

— Ovarian endometrioma: dull pelvic ache, may rupture causing acute peritonitis.

— Distorted pelvic anatomy/adhesions, impaired oocyte quality, altered tubal motility, inflammatory peritoneal environment toxic to sperm/embryo.

— Menstrual diary (cycle length, flow, pain timing on 0–10 scale).

— Response to prior NSAIDs, hormonal contraception, GnRH agents.

— Bowel/bladder symptom timing relative to menses.

— Sexual history, dyspareunia depth, impact on relationships/QoL.

— Reproductive goals — critical because it changes management entirely.

— Family history (1st-degree relatives).

— Screen for comorbid pain disorders: IBS, interstitial cystitis, migraine, fibromyalgia, depression/anxiety — present in 30–50%.

Key distinction: Primary dysmenorrhea begins within 6–12 months of menarche, responds well to NSAIDs, and resolves with cycle. Endometriosis-related (secondary) dysmenorrhea begins years after menarche, worsens progressively, and becomes refractory — a critical Step 3 history pivot point.

Classic symptom triad: dysmenorrhea + dyspareunia + dyschezia ("the 3 D's"); add infertility for the tetrad.

Pain characteristics:

Site-specific symptoms:

Infertility mechanisms:

History essentials to document:

Physical Exam Findings (and Pelvic Assessment)

— Lower abdominal/suprapubic tenderness, often diffuse.

— Surgical scars — check for incisional endometriosis nodules (cyclic pain + palpable mass at C-section or laparoscopy scar).

— Bluish or red implants on posterior vaginal fornix or cervix — pathognomonic but uncommon.

— Cervical motion may worsen pain.

— Exclude vaginal/cervical pathology mimicking dyspareunia.

— Tender nodularity of the uterosacral ligaments — the single most specific finding for deep infiltrating endometriosis.

— Fixed, retroverted uterus — suggests dense pelvic adhesions.

— Adnexal mass/tenderness — consider endometrioma.

— Posterior cul-de-sac tenderness or palpable nodule.

— Lateral cervical displacement from asymmetric scarring.

— Endometriosis itself does not cause instability.

— Ruptured endometrioma → acute peritonitis, possible hemodynamic compromise — surgical emergency mimicking ectopic pregnancy.

— Catamenial pneumothorax → tachypnea, decreased breath sounds during menses.

Step 3 management: When bimanual reveals uterosacral nodularity or a fixed uterus, order transvaginal ultrasound first and refer to gynecology for consideration of MRI and laparoscopy — these findings predict deep infiltrating endometriosis that often requires surgical, not just medical, management.

General principle: Exam is often normal, especially in early or superficial disease — a normal pelvic exam does not rule out endometriosis. Highest yield is examination during menses when lesions are most tender and palpable.

Abdominal exam:

Speculum exam:

Bimanual exam (highest-yield findings):

Rectovaginal exam: Essential when deep disease suspected — palpate rectovaginal septum for nodularity, assess for rectal involvement.

Hemodynamic considerations:

Pain mapping: Have patient point to "worst pain" — focal trigger points suggest myofascial overlay; diffuse pain suggests central sensitization, which alters treatment.

Diagnostic Workup — Initial Labs and Imaging

— Urine β-hCG — mandatory in any reproductive-age woman with pelvic pain to exclude pregnancy/ectopic.

— CBC — anemia from heavy menses or chronic disease.

— Urinalysis ± culture — exclude UTI; cyclic hematuria warrants cystoscopy.

— Vaginal/cervical swabs (GC/chlamydia) — exclude PID, especially in younger patients.

— TSH, prolactin if menstrual irregularity.

— Often elevated in endometriosis but non-specific (also up in PID, fibroids, ovarian cancer, pregnancy).

— Do not use for diagnosis or screening; may have limited role in monitoring recurrence post-op.

— Best for ovarian endometriomas — classic "ground-glass" homogeneous low-level echoes within a unilocular cyst, no internal vascularity.

— Detects deep infiltrating endometriosis of bladder, rectovaginal septum, and bowel in experienced hands (IDEA consensus protocol).

— Cannot detect superficial peritoneal implants — a normal TVUS does not exclude disease.

— Look for "kissing ovaries" sign (ovaries adherent in cul-de-sac) — highly specific.

Board pearl: A reproductive-age woman with pelvic pain + adnexal mass + negative β-hCG and a unilocular cyst with homogeneous low-level "ground-glass" echoes on TVUS = endometrioma until proven otherwise. CA-125 may be modestly elevated and should not trigger an oncology workup unless complex features (solid components, septations, vascularity) are present.

Endometriosis is a clinical diagnosis supported by imaging; definitive diagnosis is histologic via laparoscopy, but ACOG/ESHRE now endorse empirical treatment without surgical confirmation in typical presentations.

Initial labs (rule out mimics, not diagnose):

CA-125:

Transvaginal ultrasound (first-line imaging):

Transabdominal US: Useful if virgin patient or large mass extending above pelvis.

Diagnostic Workup — Advanced and Confirmatory Studies

— Indicated when deep infiltrating endometriosis is suspected (uterosacral nodularity, bowel/bladder symptoms, fixed uterus, planning surgery).

— Superior to US for rectovaginal septum, bladder wall, and bowel involvement; T1 hyperintense lesions with T2 "shading" represent hemorrhagic foci.

— Helps surgical planning and multidisciplinary referral (colorectal, urology).

— Reserved for cyclic GI bleeding, hematuria, or obstructive uropathy.

— Endometriotic implants typically extrinsic — colonoscopy may appear normal despite serosal disease.

— Direct visualization + biopsy showing endometrial glands and stroma confirms diagnosis.

— Lesions: powder-burn black, red flame, clear vesicular, white fibrotic; appearance varies with lesion age.

— Allows concurrent excision/ablation — diagnostic and therapeutic.

— No longer required before initiating empirical hormonal therapy in typical cases.

— Based on lesion size, depth, location, and adhesions.

— Poorly correlates with pain but predicts fertility outcomes — Stage IV has worst spontaneous conception rates.

Key distinction: Empirical therapy first, surgery if refractory is the modern Step 3 paradigm. Laparoscopy is indicated for: (1) failure of medical therapy after 3–6 months, (2) suspected deep infiltrating disease, (3) endometrioma >4 cm, (4) infertility evaluation when ART is being planned, or (5) need for tissue diagnosis to exclude malignancy.

Pelvic MRI:

Colonoscopy / cystoscopy / IVP:

Diagnostic laparoscopy (historical gold standard):

Staging (ASRM revised classification, Stages I–IV):

Endometriosis Fertility Index (EFI): Used post-laparoscopy to predict pregnancy probability and guide ART decisions.

Biomarkers: No validated serum biomarker for diagnosis as of current guidelines; investigational (miRNAs, glycoproteins).

Risk Stratification and First-Line Management Logic

— 1. Primary symptom: pain vs. infertility vs. mass.

— 2. Reproductive goals: desires pregnancy now, later, or not at all.

— 3. Severity/anatomy: superficial vs. deep infiltrating vs. endometrioma.

— Step 1: NSAIDs (scheduled, not prn) + combined hormonal contraceptive (continuous or cyclic).

— Step 2 (failure at 3 months): switch to progestin-only (norethindrone, DMPA, LNG-IUD, dienogest).

— Step 3: GnRH agonist (leuprolide) or antagonist (elagolix) with hormonal add-back.

— Step 4: laparoscopic excision/ablation.

— Hormonal suppression is contraindicated (prevents conception).

— Offer NSAIDs for symptom control + expedited fertility evaluation.

— Laparoscopic treatment may improve spontaneous conception in Stage I/II.

— Consider IVF directly for Stage III/IV or older patient.

— Refer to reproductive endocrinology.

— Options: expectant management (young, mild), laparoscopic excision, ovarian stimulation + IUI, or IVF (preferred for advanced disease).

— Surgical excision (cystectomy preferred over drainage/ablation — lower recurrence).

— Counsel re: diminished ovarian reserve after cystectomy — check AMH first if fertility-relevant.

Step 3 management: The decision tree always starts with "do you want to be pregnant in the next 6–12 months?" — this single question redirects half the algorithm. Hormonal suppression is the cornerstone for pain when pregnancy is not desired; it is off the table when conception is the goal.

Management is driven by three patient-specific factors — answer these first:

Pain-dominant + not currently seeking pregnancy (most common Step 3 vignette):

Pain-dominant + desires pregnancy now:

Infertility-dominant:

Endometrioma >4 cm:

Adolescents: Treat empirically with NSAIDs + OCPs; laparoscopy reserved for refractory cases.

Pharmacotherapy — First-Line Drug Regimens

— Naproxen 500 mg BID or ibuprofen 600–800 mg q6–8h, started 1–2 days before expected menses.

— Block prostaglandin synthesis; modest efficacy alone.

— Caution: GI bleeding, renal impairment, hypertension.

— Any low-dose monophasic OCP, patch, or vaginal ring.

— Continuous (skip placebo) dosing is preferred — fewer withdrawal bleeds = less pain.

— Mechanism: ovulation suppression, decidualization, reduced menstrual flow.

— Contraindications: migraine with aura, age >35 + smoker, VTE history, uncontrolled HTN, breast cancer.

— Norethindrone acetate 5–15 mg/day PO — FDA-approved for endometriosis.

— Medroxyprogesterone acetate (DMPA) 150 mg IM q3 months — caution re: BMD loss with prolonged use, delayed return to fertility.

— Levonorgestrel IUD — excellent for dysmenorrhea, reduces lesion activity locally.

— Dienogest 2 mg daily — selective progestin, well-tolerated, available in US.

— Side effects: breakthrough bleeding, mood changes, weight gain.

— Leuprolide 3.75 mg IM monthly or 11.25 mg q3 months.

— Elagolix (oral GnRH antagonist) 150 mg daily (24 mo) or 200 mg BID (6 mo).

— Induce hypoestrogenic state → hot flashes, BMD loss, vaginal dryness.

— Add-back therapy (norethindrone 5 mg ± low-dose estradiol) is standard to mitigate side effects and allow extended use beyond 6 months.

Board pearl: Before starting GnRH agonist therapy beyond 6 months, add norethindrone add-back to prevent osteoporotic bone loss — this is a high-yield Step 3 prescribing point and a frequent question stem about preventing iatrogenic harm.

NSAIDs (always first symptomatic layer):

Combined hormonal contraceptives (CHCs) — first-line hormonal:

Progestin-only therapies (second-line or first if CHC contraindicated):

GnRH analogues (third-line):

Aromatase inhibitors (letrozole): Adjunct for refractory cases, postmenopausal endometriosis, off-label.

Danazol: Largely abandoned — androgenic side effects (acne, hirsutism, voice changes).

Surgical Management and Procedures

— Failure of medical therapy (3–6 months).

— Endometrioma >4 cm or suspicious for malignancy.

— Deep infiltrating endometriosis with bowel/bladder/ureteral involvement.

— Infertility with planned conservative surgery or pre-IVF optimization.

— Acute complications: ovarian torsion, ruptured endometrioma, obstructive uropathy.

— Less adhesion formation, faster recovery, better visualization.

— Excision > ablation for deep lesions (lower recurrence, better pain relief).

— Adhesiolysis restores anatomy and may improve fertility.

— Cystectomy (stripping the cyst wall) preferred over fenestration/coagulation — lower recurrence and better spontaneous pregnancy rates.

— Trade-off: removes adjacent normal cortex → drop in AMH and ovarian reserve, especially with bilateral surgery.

— Counsel re: fertility preservation (oocyte cryopreservation) before bilateral cystectomy in young patients.

— May require multidisciplinary team — colorectal (bowel shaving/discoid/segmental resection), urology (ureterolysis, partial bladder resection).

— Significant complication risk: anastomotic leak, ureteral injury, fistula.

— Reserved for women with completed childbearing, refractory pain, after thorough counseling.

— BSO reduces recurrence but causes surgical menopause — discuss hormone therapy (estrogen alone or estrogen + low-dose progestin) post-op; risk of recurrence with estrogen-only HT is low but not zero.

— Hormonal suppression (CHC, LNG-IUD, progestin) after conservative surgery reduces recurrence and is recommended unless pregnancy desired immediately.

CCS pearl: For a patient with severe deep infiltrating endometriosis scheduled for laparoscopic excision, CCS-style orders include: pre-op CBC, type & screen, urine β-hCG, bowel prep (if rectal involvement suspected), DVT prophylaxis, prophylactic antibiotics, and gyn-onc/colorectal/urology consults as anatomy dictates.

Indications for surgery:

Laparoscopy (preferred over laparotomy):

Ovarian endometrioma — cystectomy:

Deep infiltrating disease:

Definitive surgery — hysterectomy ± bilateral salpingo-oophorectomy:

Adjuvant medical therapy post-op:

Special Populations — Renal and Hepatic Considerations

— Avoid NSAIDs in CKD (eGFR <30) or AKI — risk of further renal injury via prostaglandin-mediated afferent arteriolar constriction.

— Use acetaminophen or short-course low-dose NSAID with monitoring in mild CKD; consult nephrology for moderate impairment.

— Hepatic impairment: NSAIDs increase bleeding risk in cirrhosis (platelet dysfunction, varices) — avoid.

— Estrogen-containing CHCs: avoid in active liver disease, hepatic adenoma, decompensated cirrhosis (estrogen is hepatically metabolized; risk of cholestasis, adenoma growth).

— Progestin-only methods are generally safer in hepatic dysfunction.

— In CKD/dialysis, hormonal contraception is generally safe but assess BP control and VTE risk; progestin-only or LNG-IUD preferred in advanced kidney disease with HTN.

— Hepatic metabolism; elagolix is contraindicated in severe hepatic impairment (Child-Pugh C) and dose-reduced in moderate (Child-Pugh B).

— Use cautiously in renal disease; no significant dose adjustments for leuprolide in renal impairment.

— BMD loss is additive with CKD-mineral bone disorder — monitor DEXA.

— Rare but recognized — usually pre-existing disease reactivated by exogenous estrogen (HRT) or obesity-related peripheral aromatization.

— Workup must exclude endometriosis-associated ovarian malignancy (clear cell and endometrioid carcinomas) — concerning features: new mass, ascites, rising CA-125.

— Management: discontinue or modify HRT; aromatase inhibitors (letrozole) effective.

— Hepatic/renal impairment increases bleeding and anesthetic risk — coordinate with anesthesia for ASA classification.

Key distinction: Postmenopausal pelvic mass in a woman with prior endometriosis is malignancy until proven otherwise — clear cell and endometrioid ovarian cancers arise from endometriosis at higher rates than the general population. Surgical evaluation is mandatory, not optional.

NSAID adjustments:

Hormonal contraceptives:

GnRH analogues:

Elderly / postmenopausal endometriosis:

Perioperative considerations:

Special Populations — Adolescents, Pregnancy, and Transitions

— Endometriosis is underdiagnosed in teens; consider in any adolescent with dysmenorrhea unresponsive to NSAIDs + OCPs after 3 months.

— Müllerian anomalies with outflow obstruction (obstructed hemivagina, non-communicating uterine horn) cause early severe endometriosis from retrograde menstruation — image with MRI.

— Empirical hormonal therapy (continuous CHC or progestin) is first-line; laparoscopy if refractory.

— Counsel on long-term implications including fertility and recurrence.

— Address school absenteeism, mental health, and sexual development — adolescent gynecology specialty referral helpful.

— Pregnancy causes decidualization of implants and temporary symptom improvement, but not cure — symptoms typically return after weaning.

— Pregnancy is not therapeutic and should not be recommended as treatment.

— Increased obstetric risks: preterm birth, placenta previa, preeclampsia, SGA, miscarriage, ectopic pregnancy.

— Decidualized endometriomas can mimic ovarian malignancy on imaging during pregnancy — MRI helpful.

— Counsel early about ovarian reserve decline with age and after surgery.

— Offer fertility preservation (oocyte cryopreservation) before bilateral ovarian surgery or in young women with progressive disease.

— ART (IVF) is effective for endometriosis-associated infertility, especially Stage III/IV.

— Adolescent → adult gyn: ensure continuity of hormonal therapy and pain management plan.

— Pregnancy planning visits: stop hormonal suppression with timeline; assess for surgical optimization.

Board pearl: A young teen with severe cyclic pelvic pain + a pelvic mass + primary amenorrhea or hematocolpos suggests obstructive müllerian anomaly causing secondary endometriosis. Order MRI; do not delay diagnosis — surgical correction prevents progression.

Adolescents:

Pregnancy effects on endometriosis:

Fertility considerations:

Transition of care:

Complications and Adverse Outcomes

— Affects 30–50% of women with endometriosis via distorted anatomy, inflammation, impaired oocyte/embryo quality.

— Diminished ovarian reserve worsens with disease progression and after ovarian surgery.

— Central sensitization develops over years — pain becomes non-cyclic, refractory to hormonal therapy.

— High comorbidity with depression, anxiety, sleep disturbance, sexual dysfunction.

— Dense pelvic adhesions → bowel obstruction, hydronephrosis, frozen pelvis.

— Cyclic ureteral obstruction → silent renal damage; screen with renal US in deep disease.

— Rupture → acute peritonitis (mimics ectopic, appendicitis).

— Torsion (less common than functional cysts).

— Infection (rare, post-procedural).

— Malignant transformation: ~1% lifetime risk — endometrioid and clear cell ovarian carcinomas.

— Catamenial pneumothorax/hemothorax — recurrent right-sided pneumothorax with menses.

— Catamenial hemoptysis — pulmonary parenchymal implants.

— Bowel obstruction from full-thickness rectosigmoid involvement.

— Sciatic endometriosis — cyclic sciatica, foot drop.

— GnRH-induced bone mineral density loss, vasomotor symptoms, vaginal atrophy.

— Surgical: ureteral injury, bowel injury, anastomotic leak, ovarian reserve loss, adhesion recurrence.

— VTE risk with estrogen-containing therapy.

— Average ~$10,000/patient/year in direct and indirect costs.

— Work absenteeism, reduced productivity, relationship strain.

Step 3 management: In a patient with deep infiltrating endometriosis, screen for silent hydronephrosis with renal ultrasound even if asymptomatic — cyclic ureteral obstruction can progressively destroy kidney function before symptoms appear, and reversal requires early surgical intervention.

Infertility:

Chronic pelvic pain syndrome:

Adhesive disease:

Ovarian endometrioma complications:

Extra-pelvic complications:

Iatrogenic complications:

Quality of life and economic burden:

When to Escalate Care — Consults and Inpatient Triage

— Acute abdomen — ruptured endometrioma, ovarian torsion, bowel obstruction. Order CBC, β-hCG, lactate, type & screen, CT abdomen/pelvis with contrast; gyn surgery consult.

— Hemodynamic instability from hemorrhagic rupture → IV access ×2, fluid resuscitation, transfusion as needed, emergent laparoscopy.

— Catamenial pneumothorax → chest tube, thoracic surgery consult, hormonal suppression.

— Obstructive uropathy with AKI → urology, percutaneous nephrostomy, surgical decompression.

— Severe small bowel obstruction → NG decompression, NPO, IV fluids, surgical consult.

— Gynecology: failure of first-line therapy at 3–6 months, suspected deep disease, endometrioma >4 cm, pelvic mass, fertility concerns.

— Reproductive endocrinology/infertility: infertility >12 months (>6 months if age ≥35), advanced staging, planned IVF.

— Pain medicine: chronic refractory pain, central sensitization, multimodal management.

— Pelvic floor physical therapy: myofascial pain, dyspareunia, levator hypertonus.

— Mental health: depression, anxiety, sexual dysfunction — extremely common.

— Colorectal surgery / urology: bowel or bladder involvement.

— Gyn-oncology: suspicious adnexal mass, postmenopausal recurrence, rising CA-125.

— Recommended for deep infiltrating disease — better outcomes with experienced teams.

— Sudden severe pain, syncope, fever, vomiting, inability to urinate, hematuria, hematochezia.

CCS pearl: A woman with known endometriosis presenting with sudden severe pelvic pain + peritoneal signs + falling hematocrit — order urine β-hCG, transvaginal US, CBC, type & cross, then proceed to emergent diagnostic laparoscopy for likely ruptured endometrioma or hemorrhagic cyst. Do not delay surgery for further imaging if unstable.

Emergency department / inpatient indications:

Outpatient specialty referral:

Multidisciplinary endometriosis centers:

Patient-initiated escalation triggers to communicate at discharge:

Key Differentials — Other Gynecologic Causes

— Begins within 6–12 months of menarche; responds to NSAIDs and OCPs; no anatomic abnormality.

— Distinguishing: age of onset, response to first-line therapy, normal exam.

— Endometrial glands within the myometrium — "endometriosis interna."

— Multiparous women in 40s; heavy menstrual bleeding + dysmenorrhea + diffusely enlarged, globular, tender uterus.

— Imaging: MRI shows thickened junctional zone (>12 mm).

— Often coexists with endometriosis (up to 80% overlap).

— Treatment: LNG-IUD first-line; hysterectomy definitive.

— Heavy menstrual bleeding, bulk symptoms, dysmenorrhea.

— Enlarged, irregular, firm uterus; well-defined hypoechoic masses on US.

— Less commonly cause deep dyspareunia or cyclic dyschezia.

— Acute or chronic; sexually active women; cervical motion + adnexal tenderness, fever, vaginal discharge, positive GC/chlamydia.

— Tubo-ovarian abscess on imaging.

— Treatment: antibiotics (ceftriaxone + doxycycline ± metronidazole).

— Chronic dull pelvic pain worse with prolonged standing, premenstrual, postcoital ache.

— Dilated pelvic veins on imaging.

— Treatment: ovarian vein embolization.

— Simple cysts: thin-walled, anechoic; usually resolve.

— Distinguish endometriomas by "ground-glass" appearance.

Key distinction: Adenomyosis = diffuse, globular, tender, enlarged uterus + heavy bleeding in a multipara in her 40s. Endometriosis = uterosacral nodularity, fixed retroverted uterus, tender cul-de-sac in a 25–35-year-old. They overlap commonly, but exam findings localize the primary pathology.

Primary dysmenorrhea:

Adenomyosis:

Uterine leiomyomas (fibroids):

Pelvic inflammatory disease (PID):

Pelvic congestion syndrome:

Ovarian cysts (functional, hemorrhagic, dermoid):

Mittelschmerz: Mid-cycle ovulatory pain; brief, self-limited.

Vulvodynia / vaginismus: Superficial dyspareunia at entry vs. endometriosis-related deep dyspareunia.

Key Differentials — Non-Gynecologic Causes

— Chronic abdominal pain + altered bowel habits + bloating; not specifically cyclic.

— High comorbidity with endometriosis (up to 50%).

— Rome IV criteria for diagnosis; manage with diet, fiber, antispasmodics.

— Cyclic dyschezia/hematochezia points away from IBS toward endometriosis.

— Crohn's, ulcerative colitis — bloody stools, weight loss, systemic inflammation, extraintestinal manifestations.

— Colonoscopy + biopsy diagnostic.

— Suprapubic pain, urgency, frequency, nocturia; pain relieved by voiding.

— High overlap with endometriosis ("evil twins").

— Cystoscopy with hydrodistension may show Hunner lesions or glomerulations.

— Trigger points in abdominal wall, levator ani, piriformis.

— Carnett's sign positive (pain worse with abdominal wall tension) — points to abdominal wall, not visceral.

— Pelvic floor PT highly effective.

Board pearl: A young woman with chronic pelvic pain, dysmenorrhea, dyschezia, and urinary urgency/frequency likely has both endometriosis and interstitial cystitis — the "evil twins" of chronic pelvic pain. Screen for both with pelvic exam + bladder symptom diary (PUF questionnaire); treatment of one without the other often fails.

Irritable bowel syndrome (IBS):

Inflammatory bowel disease (IBD):

Interstitial cystitis / bladder pain syndrome:

Chronic appendicitis: Rare; right lower quadrant pain, sometimes confused with right ovarian endometrioma.

Diverticular disease: Left lower quadrant pain in older patients; less cyclic.

Musculoskeletal / myofascial pelvic pain:

Neuropathic pain: Pudendal neuralgia, ilioinguinal nerve entrapment (especially post-Pfannenstiel scar).

Psychogenic / somatic symptom disorder: Diagnosis of exclusion; coexists with organic pain — both warrant treatment.

Urinary tract pathology: UTI, nephrolithiasis (especially with cyclic hematuria — exclude with imaging).

Hernia: Inguinal or femoral; bulging mass with Valsalva.

Long-Term Plan — Maintenance, Secondary Prevention, Discharge Meds

— Goal: continuous menstrual suppression to prevent recurrence and reduce pain.

— First choice: continuous CHC, LNG-IUD, or oral progestin — well-tolerated long-term.

— Continue until pregnancy desired, menopause, or contraindication develops.

— After conservative surgery (cystectomy, excision), start hormonal suppression immediately unless conceiving — reduces recurrence by ~50%.

— Recurrence rate without suppression: ~20% at 2 years, 40–50% at 5 years.

— If BSO performed in premenopausal woman: consider estrogen-based HRT for vasomotor symptoms and bone protection.

— Risk of endometriosis recurrence with estrogen-only HRT is low; some recommend adding low-dose progestin if residual disease was present or uterus retained.

— Counsel re: signs of recurrence.

— Calcium 1000–1200 mg/day + vitamin D 800–1000 IU/day.

— Weight-bearing exercise.

— Baseline DEXA if extended use; add-back therapy mandatory beyond 6 months.

— CHC use: screen for HTN, migraine with aura, smoking, VTE history.

— Annual BP, lipid screening per USPSTF.

— Slight increase in clear cell and endometrioid ovarian cancer — no formal screening recommended, but be alert to new/changing pelvic mass, ascites, rising CA-125.

— Routinely screen for depression (PHQ-9), anxiety, sexual function (FSFI).

— Refer to therapy, sex therapy, or pelvic floor PT as needed.

Step 3 management: After laparoscopic excision of endometriosis in a 28-year-old not currently seeking pregnancy, discharge with continuous combined OCP or LNG-IUD to suppress recurrence, NSAIDs prn, calcium/vitamin D, and follow-up in 6 weeks then every 6 months for symptom reassessment.

Maintenance hormonal therapy:

Post-surgical secondary prevention:

After definitive surgery (hysterectomy ± BSO):

Bone health (especially with GnRH analogues):

Cardiovascular and VTE risk assessment:

Cancer surveillance:

Mental health and sexual health:

Follow-Up, Monitoring, and Counseling

— 6–8 weeks after starting new hormonal therapy: assess pain (0–10), bleeding pattern, side effects, adherence.

— 3 months: evaluate response — if pain persists >50% baseline, escalate therapy.

— 6 months, then annually: if stable on maintenance therapy.

— After surgery: 2 weeks (wound check), 6 weeks (initiate maintenance), then 6-month intervals.

— Pain diary — VAS scores, days of work/school missed, analgesic use.

— Menstrual diary — flow, breakthrough bleeding on hormonal therapy.

— BP — every visit, especially on CHC.

— DEXA scan — baseline and annually if on GnRH analogue >6 months.

— AMH — pre- and post-ovarian surgery if fertility relevant.

— Pelvic US — annually or as symptoms dictate; surveillance of known endometriomas.

— TSH, lipid panel, BP — annually for CHC users.

— Chronic disease framing — endometriosis is lifelong; expect flares and remissions.

— Realistic expectations — pain reduction >50% is success; complete pain elimination uncommon.

— Fertility timeline — encourage early discussion; preserve options before disease/surgery erodes reserve.

— Lifestyle: regular exercise, anti-inflammatory diet, smoking cessation, healthy weight (peripheral aromatization in obesity worsens estrogen exposure).

— Sexual health: lubricants, position changes, dilators, couples counseling.

— Support resources: patient advocacy groups (Endometriosis Foundation), peer support.

— Acupuncture, CBT, mindfulness — evidence-based adjuncts.

— Avoid chronic opioids — risk of dependence and inefficacy in central sensitization.

Board pearl: Avoid chronic opioid therapy for endometriosis pain — central sensitization is opioid-resistant, addiction risk is high, and Step 3 emphasizes opioid stewardship. Multimodal, non-opioid approaches (hormonal therapy, NSAIDs, pelvic floor PT, CBT, neuromodulators like gabapentin or duloxetine) are guideline-preferred.

Follow-up cadence (outpatient):

Monitoring parameters:

Counseling priorities:

Multimodal pain management:

Ethical, Legal, and Patient Safety Considerations

— Patients undergoing laparoscopy must be counseled re: possibility of incidental findings, bowel/bladder resection, conversion to laparotomy, oophorectomy, and hysterectomy if encountered.

— Pre-operative documentation of reproductive wishes is essential — if a patient is unconscious and a previously unsuspected fertility-threatening lesion is found, the surgeon should default to conservative management unless explicit prior consent for more extensive surgery exists.

— For young women, document discussion of ovarian reserve impact and fertility preservation options before bilateral ovarian surgery.

— Average 7–10 year delay from symptom onset to diagnosis — a recognized quality and equity gap.

— Black and Hispanic women, adolescents, and low-SES patients are disproportionately under-diagnosed — be vigilant about implicit bias when evaluating pelvic pain.

— Validate symptoms; do not dismiss as "normal periods."

— Minors may consent to contraceptive/reproductive care confidentially in most US states.

— Discuss confidentiality limits with parents and patient separately.

— Document non-opioid trials, function-based goals, PDMP review, written pain agreement for chronic pain patients.

— Avoid initiating chronic opioids for a young patient with chronic pelvic pain.

— Screen for intimate partner violence — chronic pelvic pain is a presenting symptom in some IPV survivors.

— Suspected abuse in minors triggers mandatory reporting.

— Adolescent → adult gyn handoff: ensure medication continuity, surgical history transfer, ongoing fertility counseling.

— Postoperative discharge: written instructions, red-flag symptoms, follow-up appointment scheduled before discharge.

— Excision specialists may be out-of-network; advocate for insurance coverage and accessible care.

Key distinction: When a patient is having laparoscopy for endometriosis and unexpected severe rectovaginal disease is found, do not perform bowel resection without preoperative consent — abort, discuss with patient and colorectal surgery, and return for staged definitive procedure. Performing un-consented major surgery is a sentinel patient-safety event.

Informed consent for surgery:

Diagnostic delay as a safety issue:

Adolescent confidentiality:

Opioid prescribing:

Mandatory reporting:

Transition of care:

Equity and access:

High-Yield Associations and Rapid-Fire Facts

Board pearl: If you see "chocolate cyst" + "powder-burn lesions" + "fixed retroverted uterus" + "uterosacral nodularity" — the answer is endometriosis, and the next step is hormonal suppression (if no pregnancy desired) or laparoscopic management.

Ovarian cancer link: Endometriosis predisposes to clear cell and endometrioid ovarian carcinomas (not serous).

"Chocolate cyst" = endometrioma — old blood gives the characteristic brown color.

Sampson's theory: Retrograde menstruation — the dominant pathophysiologic theory.

Meyer's theory: Coelomic metaplasia — explains rare extra-pelvic disease.

Halban's theory: Vascular/lymphatic spread — explains pulmonary and remote sites.

Catamenial pneumothorax: Right-sided, recurrent, with menses — diagnostic of thoracic endometriosis.

"Powder-burn" lesions: Classic dark blue/black peritoneal implants seen at laparoscopy.

"Ground-glass" appearance: Endometrioma on transvaginal ultrasound.

"Kissing ovaries": Bilateral ovaries adherent in the cul-de-sac — highly specific for severe endometriosis.

ASRM Staging I–IV: Based on lesion size/depth/adhesions; poorly correlates with pain, better with fertility.

Endometriosis Fertility Index (EFI): Predicts post-surgical conception probability.

Add-back therapy: Norethindrone 5 mg ± low-dose estradiol with GnRH agonist to prevent BMD loss.

Dienogest: Selective progestin, FDA-approved for endometriosis pain.

Elagolix: Oral GnRH antagonist; rapid onset, dose-flexible.

LNG-IUD: Excellent for dysmenorrhea and rectovaginal disease; also contraceptive.

Aromatase inhibitors: Letrozole — useful for refractory or postmenopausal endometriosis.

CA-125: Non-specific; elevated in many conditions; do not use for diagnosis or screening.

Risk factors: Early menarche, short cycles, nulliparity, low BMI, family history (7–10× risk).

Protective: Multiparity, prolonged lactation, exercise, late menarche.

Definitive Dx: Laparoscopy with histology — but no longer required before empirical therapy.

Surgery for endometrioma: Cystectomy > ablation — lower recurrence, better fertility.

Pregnancy effect: Temporary improvement via decidualization, not cure.

Recurrence post-op: ~50% at 5 years without maintenance hormonal therapy.

Board Question Stem Patterns

Step 3 management: The Step 3 question almost always hinges on fertility intent, disease severity, and prior treatment failures — read the stem for those three data points first, then pick the answer.

Stem 1 — Classic dysmenorrhea: 28-year-old with progressive dysmenorrhea, deep dyspareunia, and 12 months of infertility. Pelvic exam reveals tender uterosacral nodularity and a fixed retroverted uterus. Next step? → Transvaginal ultrasound; if normal, empirical hormonal therapy or laparoscopy depending on fertility goals.

Stem 2 — Adnexal mass: 32-year-old with chronic pelvic pain, β-hCG negative, TVUS shows a 5-cm unilocular cyst with "ground-glass" echoes. Diagnosis? → Endometrioma. Management? → Laparoscopic cystectomy if symptomatic, large, or affecting fertility.

Stem 3 — Adolescent: 16-year-old with severe dysmenorrhea unresponsive to NSAIDs and OCPs for 6 months. Next step? → Pelvic MRI to evaluate for müllerian anomaly; consider diagnostic laparoscopy.

Stem 4 — Add-back therapy: Woman on leuprolide for 6 months reports hot flashes; planned continuation for 6 more months. Best next step? → Add norethindrone add-back to prevent vasomotor symptoms and BMD loss.

Stem 5 — Cyclic hematuria: 30-year-old with pelvic pain and cyclic gross hematuria. Next step? → Cystoscopy + pelvic MRI for suspected bladder endometriosis.

Stem 6 — Catamenial pneumothorax: Recurrent right-sided pneumothorax in a woman with chronic pelvic pain, occurring with menses. Diagnosis? → Thoracic endometriosis. Management? → Hormonal suppression + thoracic surgery referral.

Stem 7 — Postmenopausal recurrence: 58-year-old on estrogen-only HRT (post-hysterectomy for endometriosis) develops pelvic pain and a new adnexal mass. Concern? → Endometriosis recurrence vs. clear cell ovarian carcinoma. Next step? → Pelvic imaging, CA-125, gyn-onc referral.

Stem 8 — Infertility: 35-year-old with Stage III endometriosis desires pregnancy. Best management? → Direct to IVF rather than additional surgery, given age and stage.

Stem 9 — Ruptured endometrioma: Known endometriosis patient with sudden severe pelvic pain, peritoneal signs, falling H/H. Action? → Resuscitate + emergent laparoscopy.

One-Line Recap

Endometriosis is a chronic, estrogen-dependent, inflammatory disorder of ectopic endometrial-like tissue causing dysmenorrhea, dyspareunia, dyschezia, and infertility, managed by tailoring therapy to the patient's primary symptom and reproductive goals — empirical hormonal suppression (continuous CHC or progestin) for pain when pregnancy is not desired, and laparoscopic excision or IVF when surgery or fertility demands it.

Board pearl: Master the pivot — fertility intent + symptom dominance + disease anatomy — and every Step 3 endometriosis vignette becomes algorithmic.

Suspect endometriosis in any reproductive-age woman with cyclic, progressively worsening dysmenorrhea, deep dyspareunia, dyschezia, or unexplained infertility — diagnostic delay averages 7–10 years and is a recognized health-equity gap.

Diagnose clinically; TVUS detects endometriomas and deep disease; MRI for surgical planning; laparoscopy with histology is gold standard but no longer required before initiating empirical therapy per ACOG/ESHRE.

Treat based on the cardinal question — does the patient want pregnancy now? If no: NSAIDs + continuous CHC → progestin (norethindrone, LNG-IUD, dienogest) → GnRH analogue with add-back → laparoscopic excision. If yes: refer to REI; consider expedited surgery (Stage I/II) or IVF (Stage III/IV or age ≥35); avoid hormonal suppression.

Prevent recurrence post-operatively with maintenance hormonal therapy (50% reduction); monitor BMD on GnRH analogues; screen for comorbid IBS, IC, depression, and chronic pelvic pain; avoid chronic opioids; remain alert to the small but real risk of clear cell and endometrioid ovarian malignancy, especially in postmenopausal patients with new pelvic mass.